Crohn's & Colitis 360最新文献

{"title":"Acne therapy with isotretinoin is well tolerated in patients with established inflammatory bowel disease: a retrospective, single center study.","authors":"Marley Cutrona, Ahuva Cices, Marla C Dubinsky, Elizabeth A Spencer","doi":"10.1093/crocol/otag110","DOIUrl":"10.1093/crocol/otag110","url":null,"abstract":"<p><strong>Background: </strong>Early case reports and observational studies have suggested an association between isotretinoin and inflammatory bowel disease (IBD). However, large cohort studies and meta-analyses have not demonstrated a meaningful association between isotretinoin use and IBD development. Most prior research has focused on incident IBD risk, with limited attention to disease activity among patients with established IBD.</p><p><strong>Methods: </strong>We conducted a single-center retrospective cohort study of patients with Crohn's disease (CD) or ulcerative colitis (UC) treated with isotretinoin between 2015 and 2025. Inclusion required at least 1 IBD assessment within the 4 months before and 12 months after isotretinoin initiation. Disease activity was assessed using Harvey-Bradshaw Index (HBI), partial Mayo score (pMS), inflammatory biomarkers, and in some patients, intestinal ultrasound and fecal calprotectin. The primary outcome was composite IBD status change, defined as new clinical activity (Δ ≥ 1 in HBI/pMS), or isotretinoin discontinuation attributed to IBD activity.</p><p><strong>Results: </strong>Thirty-seven patients met inclusion criteria (57% CD, 43% UC). Most patients were in clinical remission at baseline (86%). Following isotretinoin exposure, 92% remained in remission, with no significant changes in HBI, pMS, erythrocyte sedimentation rate, C-reactive protein, or fecal calprotectin. IBD status change occurred in 4 patients (11%), with events largely attributable to underlying IBD-related factors, including biologic transitions, anti-drug antibody development, or medication dose adjustments.</p><p><strong>Conclusions: </strong>Among patients with established, well-controlled IBD, isotretinoin was not associated with clinically meaningful worsening of disease activity, supporting its use in carefully selected patients with stable disease.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 4","pages":"otag110"},"PeriodicalIF":1.8,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13675085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary intake in patients with ileal pouch-anal anastomosis: a cross-sectional comparative study.","authors":"Emre Kiliç, Ole Thorlacius-Ussing, Sabrina Just Kousgaard","doi":"10.1093/crocol/otag104","DOIUrl":"https://doi.org/10.1093/crocol/otag104","url":null,"abstract":"<p><strong>Background: </strong>Ileal pouch-anal anastomosis (IPAA) is associated with good long-term outcomes, yet pouchitis remains a common complication. Although antibiotics are first-line therapy, recurrent disease often leads to repeated use with declining efficacy. Dietary interventions have shown promise, but evidence and consensus remain limited. The aim of this study was to compare dietary intake between IPAA patients with chronic pouchitis, IPAA patients with a normally functioning pouch, and healthy controls.</p><p><strong>Methods: </strong>This cross-sectional study recruited participants between November 2017 and October 2022. Participants were divided into 3 groups: patients with chronic pouchitis, patients with a normally functioning pouch, and healthy controls with an intact colon. Dietary intake over the previous 12 months was assessed using a food frequency questionnaire. Foods were categorized into groups and reported as servings per week.</p><p><strong>Results: </strong>The study included 30 participants with chronic pouchitis, 30 with a normally functioning pouch, and 82 healthy controls. Compared with the normal pouch function group, participants in the chronic pouchitis group consumed significantly more refined grains (mean difference [MD] 3.0; <i>P</i> = .045) and chocolate and candy (MD 2.5; <i>P</i> = .011). Compared with healthy controls, the chronic pouchitis group had a higher intake of sweets (MD 5.5; <i>P</i> = .001), refined grains (MD 3.8; <i>P</i> = .006), crispbread (MD 5.0; <i>P</i> < .001), and chocolate and candy (MD 2.6; <i>P</i> = .007).</p><p><strong>Conclusion: </strong>Dietary intake was generally similar between groups, but patients with chronic pouchitis reported higher consumption of starchy and sugar-rich foods. This dietary pattern may be associated with pouchitis, highlighting the need for interventional studies to assess causality.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 4","pages":"otag104"},"PeriodicalIF":1.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13680099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149227404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fatigue burden and patient attribution across remission states in inflammatory bowel disease: a longitudinal cohort study.","authors":"Arun Swaminath, Jakob Saidman, Jeremy Polman, Laura Durbin, Rachel Maggi, Troy Laurence, Keith Sultan","doi":"10.1093/crocol/otag109","DOIUrl":"https://doi.org/10.1093/crocol/otag109","url":null,"abstract":"<p><strong>Background and aims: </strong>Fatigue is common in inflammatory bowel disease (IBD), but prior work has largely focused on symptomatic disease activity rather than progressively objective remission states. We evaluated the relationship between fatigue and hierarchical remission depth, repeated changes in remission status, and patients' attribution of fatigue to IBD.</p><p><strong>Methods: </strong>Adults with confirmed IBD completed PROMIS Fatigue surveys at 2 tertiary-care centers. PROMIS Fatigue was analyzed continuously and as clinically significant fatigue (T-score ≥55). Remission was classified hierarchically as no remission, physician-global-assessment (PGA)-defined clinical remission, endoscopic remission, or histologic remission. Visit-level repeated measures were analyzed using a linear mixed-effects model. First-visit logistic regression evaluated clinically significant fatigue after adjustment for anxiety, depression, anemia, and IBD subtype; corticosteroid exposure was added in a sensitivity model. Attribution analyses included only explicit Yes or No responses.</p><p><strong>Results: </strong>We surveyed 481 patients, contributing 900 surveys. PGA-defined clinical, endoscopic, and histologic remission remained associated with lower mean PROMIS Fatigue T-scores than no remission (adjusted differences -3.68, -3.45, and -3.27 points; all <i>P</i> ≤ .001). No remission remained associated with clinically significant fatigue after adjustment for anxiety, depression, anemia, IBD subtype (OR 2.75, 95% CI, 1.83-4.14), and for corticosteroid exposure (OR 2.34, 95% CI, 1.52-3.58). Attribution of fatigue to IBD differed by remission status (<i>P</i> < .000000001). Findings remained significant when objective remission was restricted to colonoscopy within 180 days of PROMIS completion (adjusted OR 2.23, 95% CI, 1.42-3.49).</p><p><strong>Conclusion: </strong>Remission was associated with lower fatigue burden, and patients in objective remission were less likely to attribute fatigue to IBD. These observational findings support assessing inflammatory disease control early in the evaluation of fatigue while also evaluating sleep, mood, anemia, pain, medications, and other non-inflammatory contributors.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 4","pages":"otag109"},"PeriodicalIF":1.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13649359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and effectiveness of carotegrast methyl in patients with ulcerative colitis: an interim report of post-marketing surveillance in Japan.","authors":"Masayuki Saruta, Yoshiharu Miura, Mie Iwaida, Minami Umeyama, Shinsuke Kurosu, Kiyotoshi Kuramoto, Kenji Watanabe","doi":"10.1093/crocol/otag105","DOIUrl":"10.1093/crocol/otag105","url":null,"abstract":"<p><strong>Background: </strong>The first multicenter, prospective post-marketing surveillance (PMS) in Japan was conducted to confirm the safety and effectiveness of carotegrast methyl (hereafter referred to as carotegrast) in the routine clinical practice for ulcerative colitis (UC) in Japan. Here, we report the results of the interim analysis of PMS.</p><p><strong>Methods: </strong>The ongoing PMS was initiated in June 2022 and will be continued until May 2028. Study patients are individuals with moderately active UC who were refractory or intolerant to 5-aminosalicylic acid, and who started carotegrast therapy for the first time. An interim analysis was conducted based on the data cut-off (March 27, 2025).</p><p><strong>Results: </strong>Safety and effectiveness analysis sets included 296 and 290 patients, respectively. In the safety analysis set, 36.8% of patients received carotegrast for <8 weeks and 63.2% for ≥8 weeks. The most common reason for treatment discontinuation was inadequate effectiveness in 44.0% of patients who received carotegrast for <8 weeks, and symptom improvement in 66.8% for ≥8 weeks. Adverse drug reactions (ADRs) were reported in 25 patients (8.45%). No serious ADRs, ADRs relevant to progressive multifocal leukoencephalopathy, and central nervous system-related ADRs were reported. No pregnancies were reported. One patient (0.34%) experienced an ADR of pyelonephritis related to infections. The proportions of patients with clinical response, clinical remission and rectal bleeding disappearance (defined by using partial Mayo score) were 146/185 (78.9%), 133/189 (70.4%) and 137/190 (72.1%) after 8 weeks carotegrast administration, respectively.</p><p><strong>Conclusions: </strong>No new safety and effectiveness concerns were identified in the interim analysis for PMS.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 4","pages":"otag105"},"PeriodicalIF":1.8,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13644535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attentional variability as a cognitive marker of clinical activity in Crohn's disease.","authors":"Andreza Maia, Juliana Janeiro Schmidt, Carlos Eduardo Brandão Mello, Guilherme Janeiro Schmidt, Yolanda Faia Manhães Tolentino, Márcia Maria Amendola Pires, Ana Caroliny da Silva, Julia Dias Guimarães Silva, Marcia Lyrio Sindorf, Sergio Luis Schmidt","doi":"10.1093/crocol/otag099","DOIUrl":"10.1093/crocol/otag099","url":null,"abstract":"<p><strong>Background: </strong>Behavioral and cognitive manifestations have been increasingly recognized in Crohn disease (CD), yet the specific behavioral domains associated with clinical activity remain incompletely characterized. Although reduced response speed has been proposed as a key feature, moment-to-moment fluctuations in performance may better capture behavioral instability related to systemic inflammation. We examined behavioral variability and attentional performance in CD and their relationship with clinical activity.</p><p><strong>Methods: </strong>In this case-control study, patients with CD of at least 1 year's duration (<i>n</i> = 31) and healthy controls (<i>n</i> = 37) completed a short, computerized attention test assessing sustained-attention, focused-attention, inhibitory control, and processing speed. Group differences were evaluated using multivariate and univariate analyses of covariance. Binary logistic regression evaluated the discriminative ability of attentional measures, while correlations and regression analyses examined associations with disease activity measured by the Harvey-Bradshaw Index (HBI).</p><p><strong>Results: </strong>Fifty percent of patients with CD were in clinical remission. Compared with controls, patients with CD demonstrated significantly greater attentional variability and higher omission error rates, whereas mean response speed did not differ significantly. Within the CD cohort, sustained attention was significantly associated with disease activity and was the only subdomain predicting HBI scores. Patients in clinical remission continued to show impairments in sustained and focused attention compared with controls, whereas response speed was unaffected.</p><p><strong>Conclusion: </strong>CD is associated with selective alterations in attentional stability rather than generalized slowing. Attentional variability tracks clinical activity and remains detectable during remission, suggesting that sustained attention may represent a sensitive cognitive marker of ongoing disease impact.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 3","pages":"otag099"},"PeriodicalIF":1.8,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13589784/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149011980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, timing and risk factors of extraintestinal manifestations in inflammatory bowel disease: a retrospective cohort study from a German tertiary referral center.","authors":"Fotios Fousekis, Panagiotis Garantziotis, André Jefremow, Christina Bergmann, Maria Gabriella Raimondo, Andreas Ramming, Georg Schett, Markus F Neurath, Raja Atreya","doi":"10.1093/crocol/otag100","DOIUrl":"https://doi.org/10.1093/crocol/otag100","url":null,"abstract":"<p><strong>Background: </strong>Extraintestinal manifestations (EIMs) are a frequent and clinically significant feature of inflammatory bowel disease (IBD), contributing to morbidity and impaired quality of life.</p><p><strong>Objectives: </strong>To investigate the prevalence, spectrum, timing, and risk factors of EIMs in a large cohort of patients with IBD.</p><p><strong>Methods: </strong>In this retrospective cohort study, adult patients with ulcerative colitis (UC) or Crohn's disease (CD) followed at a German tertiary referral center were included. Electronic medical records were reviewed to identify specialist-confirmed EIMs, their timing relative to IBD diagnosis, and associated demographic and disease-related factors.</p><p><strong>Results: </strong>A total of 817 patients with IBD (527 CD, 290 UC) were included, with a median disease duration of 11 years (IQR 6-19). EIMs were identified in 227 patients (27.8%), with rheumatologic (17.4%) and cutaneous (8.9%) manifestations being the most frequent. Most patients had one EIM (70%), while 30% developed multiple manifestations. Female sex (OR 2.88; 95% CI 2.08-4.02, <i>P</i> < .001), longer IBD duration (OR 1.02 per year; 95% CI 1.01-1.04, <i>P</i> = .002), and CD (OR 1.57; 95% CI 1.08-2.29, <i>P</i> = .018) were independently associated with EIM development. EIMs occurred before or concurrently with IBD diagnosis in 20.7% of affected patients. Kaplan-Meier analysis demonstrated a continuous increase in the cumulative probability of developing EIMs over time, reaching approximately 27% at 15 years of follow-up.</p><p><strong>Conclusion: </strong>EIMs affect more than one quarter of patients with IBD and may precede or coincide with intestinal disease onset. Female sex and CD appear to be independent risk factors. These findings highlight the importance of early recognition and long-term surveillance of EIMs in patients with IBD.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 4","pages":"otag100"},"PeriodicalIF":1.8,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13637596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum amyloid a as a high-resolution indicator of mucosal healing in ulcerative colitis.","authors":"Kotaro Akita, Yoshihiro Yokoyama, Yuta Shimomori, Tomoe Kazama, Masanori Nojima, Hiroshi Nakase","doi":"10.1093/crocol/otag097","DOIUrl":"10.1093/crocol/otag097","url":null,"abstract":"<p><strong>Background: </strong>Endoscopy is the standard for assessing mucosal activity in ulcerative colitis (UC), but reliable biomarkers are needed. This study evaluated serum amyloid A (SAA) as a potential biomarker by comparing it with established markers in UC.</p><p><strong>Methods: </strong>We retrospectively evaluated 182 patients with UC who underwent blood and stool testing within 14 days of colonoscopy at a tertiary care hospital between April 2017 and January 2025. Patients were classified into 4 groups according to the Mayo Endoscopic Subscore (MES). Baseline characteristics and laboratory and endoscopic variables were compared across groups.</p><p><strong>Results: </strong>Serum SAA levels demonstrated strong positive correlations with leucine-rich α-2-glycoprotein (LRG) (<i>r</i> = 0.752) and C-reactive protein (CRP) (<i>r</i> = 0.717). Significant associations were also observed between SAA and MES, Mayo score, partial Mayo score, and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (all <i>P</i> < .01). SAA identified active endoscopic inflammation (MES ≥ 2) at a cutoff value of 4.1 mg/L, with an area under the curve (AUC) of 0.813 (95% CI, 0.731-0.894), sensitivity of 0.804, and specificity of 0.741. In addition, SAA differentiated MES 0 from MES 1 at a cutoff value of 2.6 mg/L, yielding an AUC of 0.683 (95% CI, 0.470-0.897), sensitivity of 0.706, and specificity of 0.714.</p><p><strong>Conclusions: </strong>SAA exhibits diagnostic performance comparable to, and in some respects exceeding, that of established inflammatory biomarkers in UC. Importantly, SAA effectively discriminates between MES 0 and MES 1, supporting its potential role as a sensitive marker of mucosal healing.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 3","pages":"otag097"},"PeriodicalIF":1.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13570589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148954846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colombian registry of inflammatory bowel disease in pediatrics.","authors":"Fernando Sarmiento Quintero, Ana María Castañeda Figueroa, Diana Victoria Mora Quintero, Claudia Patricia Sánchez Franco, Lina Eugenia Jaramillo Barberi, Sergio Andrés Prado Baquero, Marco Alberto Suárez Urueña, Andrea Natalia Pedraza Peña, Stephanía Peña Hernández, Karol Andrea Martínez Portilla, Lina Baños Rocha, Luz Esthella Tovar Correa, Diana Catalina López Mora, Catalina Pallejá López, Diana Paola Sánchez Hernández, Mónica María Contreras Ramírez, Catalina Ortiz Piedrahita, Claudia Liliana Losada Gómez, Alejandra Wilches Luna, Diana María Quimbayo Wilches, Verónica Botero Osorio, Rafael Milanés Romero, Andrés Enríquez Calvache, Melquisedec Vargas Sandoval, Fernando Medina Monroy, Hugo Laignelet Hernández, Wilson Daza Carreño, José Fernando Vera Chamorro, Ailim Margarita Carias Domínguez, Johana Hincapié Butto, Maira Patricia Sánchez Pérez, Carlos Cuadros Mendoza, Otto Calderón Guerrero, María Mercedes Naranjo Vergara, Clara Eugenia Plata García, Luis Carlos Ramírez Urrego, Rodrigo De Vivero Camacho, Sandra Helena Paipilla Monroy, Luz Eugenia Aragón Calvo, Mariastella Serrano","doi":"10.1093/crocol/otag038","DOIUrl":"10.1093/crocol/otag038","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory bowel disease (IBD) has significantly increased over the past two decades. However, registries in Latin America remain scarce, prompting the creation of the Colombian pediatric IBD registry for patients under 18 years of age, designed as a continuous and periodically assessed database.</p><p><strong>Methods: </strong>A descriptive, longitudinal, ambispective, and multicenter observational study was conducted in children aged 0-18 years between January 1999 and December 2021. The analysis was performed based on the age of onset (Paris classification), with subdivisions for very early onset and phenotypes using the Pediatric IBD-classes algorithm. Data were collected in REDCap and analyzed with STATA 15.1.</p><p><strong>Results: </strong>A total of 209 patients were included, 54.5% male. The median age at diagnosis was 12.3 years (IQR 8.5-14.6). Phenotype distribution included: 104 (53.06%) typical ulcerative colitis (TUC), 52 (26.53%) Crohn's disease (CD), 18 (9.18%) unclassifiable IBD (U-IBD), 11 (5.61%) colonic Crohn's disease (CCD), and 11 (5.61%) atypical ulcerative colitis (AUC). The median time to diagnosis was 6.6 months, and treatment began after a median of 11.2 days. Coffee-cultivation zone 39%. Extraintestinal manifestations were reported in 43.9% of cases. Initial treatments included mesalamine ± steroids (35.86%), immunomodulators ± steroids (32%), exclusive/partial enteral nutrition (11.41%), and biologics ± immunomodulators (20.65%), which increased to 57.7% during follow-up. Relapse occurred in 53.26% of patients, while 35.32% achieved remission.</p><p><strong>Conclusions: </strong>This registry highlights the increasing incidence of pediatric IBD in Latin America, providing valuable insights into clinical presentations, diagnostic delays, treatment strategies, and outcomes, while revealing regional and global disparities.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 3","pages":"otag038"},"PeriodicalIF":1.8,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13557115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced therapy options, choice, access, and treatment empowerment for inflammatory bowel disease (ADVOCATE-IBD): a UK-wide semi-structured interview study exploring patient preferences around advanced therapy decisions in inflammatory bowel disease.","authors":"Ronit Hardasani, Shellie Jean Radford, Mohammad Farhad Peerally","doi":"10.1093/crocol/otag098","DOIUrl":"10.1093/crocol/otag098","url":null,"abstract":"<p><strong>Background: </strong>Advanced therapies, including biologics and small molecule drugs, are increasingly used in the management of inflammatory bowel disease (IBD), but their diverse characteristics can influence patient treatment choices and experiences. Understanding patient priorities and practicing shared decision-making can optimize treatment satisfaction and adherence. This qualitative study explored patient experiences on advanced therapies to identify factors influencing treatment decisions aiming to develop a practical tool supporting shared decision-making when initiating or switching treatments.</p><p><strong>Method: </strong>Using purposive sampling, participants on advanced therapies for moderate-to-severe IBD were recruited through Crohn's & Colitis UK and social media until achieving data saturation. Semi-structured interviews were conducted using a topic guide developed from literature review and patient representative input. Audio recordings were transcribed and analyzed using reflexive thematic analysis.</p><p><strong>Results: </strong>Of 26 participants, most were female (73.1%) and using Vedolizumab (30.7%) or Infliximab (26.9%). The age group 31-40 (34.6%) was most commonly represented, and 46.2% had ulcerative colitis. All participants were in self-reported clinical remission. Four overarching themes were identified: embedding treatment realities into daily routines; negotiating the tension between therapeutic benefits and potential risks; navigating formal and informal support structures; and asserting agency in treatment decisions.</p><p><strong>Conclusion: </strong>Patient decision-making around advanced therapies for the management of moderate-to-severe IBD is influenced by treatment practicality and life impact, balancing efficacy and risk management, access to healthcare support networks, and involvement in care decisions. The Advanced therapy options, choice, access, and treatment empowerment for IBD tool, developed from these findings, provides clinicians with a framework to understanding individual patient priorities and values, supporting meaningful shared decision-making.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 3","pages":"otag098"},"PeriodicalIF":1.8,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Considerations in reviewing network meta-analyses of heterogeneous clinical trial designs: a methodological review in Crohn's disease and ulcerative colitis.","authors":"","doi":"10.1093/crocol/otag095","DOIUrl":"https://doi.org/10.1093/crocol/otag095","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/crocol/otag050.].</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 3","pages":"otag095"},"PeriodicalIF":1.8,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13600420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}